Daily Endocrinology Research Analysis
Analyzed 95 papers and selected 3 impactful papers.
Summary
Across endocrinology and metabolic medicine, three studies stand out: a subgroup analysis from the FLOW trial shows semaglutide reduces kidney failure and all-cause mortality in type 2 diabetes with CKD regardless of cardiovascular status; a phase 2 randomized trial demonstrates robust glycemic efficacy and acceptable safety of an oral nonpeptide GLP-1 receptor agonist (HRS-7535); and a novel [68Ga]Ga-Trivehexin PET/CT markedly outperforms MIBI SPECT/CT for localizing hyperfunctioning parathyroid tissue in primary hyperparathyroidism.
Research Themes
- GLP-1–based therapies for cardio-renal-metabolic disease
- Oral small-molecule incretin receptor agonists
- Advanced molecular imaging for endocrine surgery planning
Selected Articles
1. Kidney and Survival Benefits of Semaglutide in Diabetes With Chronic Kidney Disease: FLOW Trial Cardiovascular Subgroup Analyses.
In FLOW, once-weekly semaglutide reduced the primary kidney composite outcome and all-cause mortality consistently across subgroups with or without ASCVD, heart failure, or high total CVD risk. Hazard ratios for the kidney outcome ranged from 0.67 to 0.80 across subgroups, with numbers needed to treat at 3 years of 13 (heart failure), 17 (high risk), and 22 (ASCVD). All-cause death was also reduced with HRs ~0.71–0.82.
Impact: This analysis strengthens the generalizability of semaglutide’s kidney and survival benefits in T2D with CKD across diverse cardiovascular profiles, informing broad clinical use beyond traditional high-risk categories.
Clinical Implications: Consider once-weekly semaglutide to slow CKD progression and reduce mortality in T2D with CKD irrespective of ASCVD or heart failure status, alongside guideline-directed therapies (e.g., SGLT2 inhibitors, RAAS blockade).
Key Findings
- Semaglutide reduced the primary kidney outcome in participants with ASCVD (HR 0.80, 95% CI 0.63–1.02) and without ASCVD (HR 0.74, 95% CI 0.62–0.89); interaction P=0.62.
- Benefits were consistent in heart failure (HR 0.67, 95% CI 0.49–0.93) and non–heart failure subgroups (HR 0.79, 95% CI 0.67–0.93); interaction P=0.40.
- Numbers needed to treat at 3 years to prevent one primary kidney outcome: 13 (heart failure), 17 (high total CVD risk), 22 (ASCVD).
- All-cause mortality was reduced across subgroups (e.g., HR 0.75 in heart failure; HR 0.81 without heart failure).
Methodological Strengths
- Large, randomized, double-blind trial framework with prespecified cardiovascular subgroups
- Consistent effects across multiple clinically relevant strata and outcomes (kidney composite, all-cause death)
Limitations
- Subgroup analyses may be underpowered, with CIs including unity in some strata
- Specific follow-up duration details not fully delineated in the abstract
Future Directions: Evaluate additive/interactive effects with SGLT2 inhibitors, cost-effectiveness across risk strata, and real-world implementation pathways for broad CKD populations.
BACKGROUND: Cardiovascular disease increases risks of chronic kidney disease (CKD) progression and mortality in type 2 diabetes. OBJECTIVES: The study sought to assess semaglutide effects on kidney and survival outcomes by baseline cardiovascular status in the FLOW trial. METHODS: Participants with type 2 diabetes and CKD were randomized to once-weekly subcutaneous semaglutide 1.0 mg vs placebo. Baseline subgroups included atherosclerotic cardiovascular disease (ASCVD), heart failure, and high total cardiovascular disease risk without established cardiovascular disease (10-year PREVENT [Predicting Risk of cardiovascular disease EVENTs] score ≥20%). The primary outcome was ≥50% estimated glomerular filtration rate (eGFR) decline, eGFR <15 mL/min/1.73 m
2. HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin: A Randomized Clinical Trial.
In 194 randomized adults with T2D on metformin, once-daily oral HRS-7535 reduced HbA1c by −0.94% to −1.57% (placebo-adjusted) over 16 weeks, with up to 63.2% achieving HbA1c <7.0%. The 90-mg group showed greater weight reduction than placebo (−2.63% vs −1.30%), and safety was consistent with GLP-1RAs, mainly mild-to-moderate GI events and no severe hypoglycemia.
Impact: Demonstrates clinically meaningful glycemic efficacy of a nonpeptide oral GLP-1RA that does not require fasting or injection, potentially improving acceptability and access compared with current agents.
Clinical Implications: If confirmed in phase 3, HRS-7535 could expand GLP-1RA use to patients preferring or requiring oral, non-fasting administration, offering robust HbA1c lowering with modest weight loss and a familiar GI-tolerability profile.
Key Findings
- Placebo-adjusted HbA1c reductions at week 16 ranged from −0.94% to −1.57% across 15–90 mg doses (all P<0.001).
- HbA1c <7.0% achieved in 48.7%–63.2% with HRS-7535 vs 15.4% with placebo.
- Body weight decreased more with 90 mg HRS-7535 (−2.63%) vs placebo (−1.30%).
- Adverse events were predominantly mild-to-moderate GI events; no level 2–3 hypoglycemia or hepatotoxicity signals.
Methodological Strengths
- Phase 2, double-blind, placebo-controlled, dose-ranging design across four doses
- Prospective trial registration (NCT05759897) and multicenter conduct
Limitations
- Short duration (16 weeks) limits assessment of durability and long-term safety
- Conducted exclusively in China; generalizability and cardiometabolic outcomes require phase 3 confirmation
Future Directions: Phase 3 trials assessing durability, cardiovascular and kidney outcomes, head-to-head comparisons with injectable and other oral incretin agents, and adherence/acceptability in real-world settings.
IMPORTANCE: Oral small-molecule glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may address limitations of injectable and peptide-based agents for type 2 diabetes. OBJECTIVE: To evaluate the efficacy and safety of HRS-7535, an oral nonpeptide GLP-1 RA, as add-on therapy among adults with type 2 diabetes inadequately controlled with metformin. DESIGN, SETTING, AND PARTICIPANTS: This 16-week, phase 2, double-blind, placebo-controlled randomized clinical trial was conducted at 44 centers in China. Adults aged 18 to 75 years with type 2 diabetes, hemoglobin A1c (HbA1c) levels ranging from 7.5% to 11.0%, and receiving stable metformin therapy were enrolled between May 10 and December 18, 2023. Data were analyzed from May 8 to 22, 2024.
3. A novel imaging approach in hyperparathyroidism: [68Ga]Ga-Trivehexin PET/CT.
[68Ga]Ga‑Trivehexin PET/CT localized hyperfunctioning parathyroid tissue in 92% of patients and 98% of lesions versus 74% and 58% by MIBI SPECT/CT, respectively (P<0.05). It revealed focal uptake in many MIBI‑negative/equivocal lesions, and early acquisitions sufficed, with limited added value of delayed imaging.
Impact: Provides compelling head-to-head evidence that a novel PET tracer substantially outperforms standard MIBI SPECT/CT for PHPT localization, with potential to shift first-line imaging and improve surgical planning.
Clinical Implications: Adopting [68Ga]Ga‑Trivehexin PET/CT, particularly in multiglandular, subcentimetric, or reoperative/persistent PHPT, may enhance localization accuracy, reduce negative explorations, and streamline operative strategies; early-time imaging appears adequate.
Key Findings
- Patient-based correct localization: 92% with [68Ga]Ga‑Trivehexin PET/CT vs 74% with MIBI SPECT/CT.
- Lesion-based detection: 98% (49/50) with [68Ga]Ga‑Trivehexin PET/CT vs 58% (29/50) with MIBI (P<0.05).
- Detected 18 lesions with negative/equivocal MIBI; early acquisition sufficient with minimal benefit from delayed imaging.
- Dynamic imaging showed rapid lesion-to-background contrast plateauing at ~25 minutes.
Methodological Strengths
- Within-patient head-to-head comparison of PET/CT versus MIBI SPECT/CT
- Quantitative assessment (SUVmax, lesion-to-background) and subgroup analyses (MEN-1, persistent disease)
Limitations
- Single-center retrospective design with modest sample size (38 patients, 50 lesions)
- Limited dynamic imaging subset and lack of prospective surgical outcome correlation in the abstract
Future Directions: Prospective, multicenter diagnostic accuracy and impact studies versus first-line standards, cost-effectiveness analyses, and integration into surgical algorithms, especially in multiglandular disease.
PURPOSE: To evaluate the diagnostic performance of [68Ga]Ga-Trivehexin PET/CT for localizing hyperfunctioning parathyroid tissue in patients with primary hyperparathyroidism (PHPT) and to compare it with [99mTc]Tc-MIBI scintigraphy with SPECT/CT (MIBI scan). METHODS: In this retrospective study, patients with biochemically confirmed PHPT underwent both MIBI scan and [68Ga]Ga-Trivehexin PET/CT. Patient- and lesion-based detection rates were compared between modalities. [68Ga]Ga-Trivehexin PET/CT was acquired at approximately 40 ± 20 min after injection; delayed imaging at 80 ± 20 min was performed in a subset. Dynamic PET imaging was performed in three patients.